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Materials
All Proteinogenic Fmoc-amino acids were purchased from CEM. The remaining Fmoc-amino acids, including Fmoc-Agl-OH, Anhydrous lithium chloride was purchased from Alfa-Aesar. HPLC grade acetonitrile (ACN), dichloromethane (DCM), dimethylformamide (DMF) and methanol (MeOH) were purchased from Merck. All chemicals were used without further purification. All materials required for the expression and purification of TriF pep , as well as D-peptidase assays have been previously described. 3
II. General procedure for peptide synthesis
Peptides were synthesized on a CEM Liberty 12 Microwave Peptide Synthesizer. Solid phase synthesis was carried out on a 0.1 mmol scale using Fmoc chemistry on 2-chlorotrityl (2CT) resin preloaded with Ala (0.6 mmol/g). Factory settings were used for all coupling and deprotection cycles. Asymmetrically protected amino acids were used as 0.2 M solutions of DMF with amino acid subunits being coupled using HATU as the activator and DIPEA as the activator base and heated to 70 °C (50 °C for cysteine residues) for 5 minutes. Fmoc residues were deprotected using a 20 % solution of piperidine in DMF.
Upon completion of synthesis, the peptide resin was washed with CH 2 Cl 2 (3 x 5 mL) in a glass-fritted filter funnel and dried under vacuum suction for 15 min. Dried peptide resin was transferred to a vial containing TFA:TIPS:water (95:2.5:2.5, 10 mL) and heated at 37 °C for 2 h with periodic manual shaking. For cysteine-containing peptides, an alternate cleavage cocktail of TFA:EDT:TIPS:water (95:2.5:2.5:1, 10.1 mL) was used under the same reaction conditions. The resin beads were then removed by filtration through glass wool and the filtrate was concentrated in vacuo. Et 2 O (5 mL) was added to precipitate crude peptide and the resulting suspension transferred to 2 mL centrifuge tubes. The tubes were centrifuged for 1 min using a microcentrifuge and the liquid decanted. Pellets were resuspended in Et 2 O (1 mL), vortexed, centrifuged and the liquid decanted to yield crude peptide pellets. 
III. Purification and analysis of peptides

IV. Unsuccessful attempts to synthesize cyclic TriA 1 analogues by Ring-Closing Metathesis
Method 1 -RCM of full-length peptides on resin: Oct-TriA 1 (5-D-Agl, 9-Agl)-2CT (12) and Oct-TriA 1 (5-D-Sac, 9-Sac)-2CT (13) were synthesized using Fmoc-SPPS. A small amount of peptide was cleaved from resin (~ 1 mg) and analysed by HRMS as previously described to confirm the correct starting material had been prepared. The dried resin of each synthesis was weighed, and the total mass assumed to correlate to 0.1 mmol peptide. The on-resin peptide (0.0882 mmol) was added to a solution of Hoveyda-Grubbs Second Generation Catalyst (11 mg, 0.0176 mmol, 0.2 equiv.) in anhydrous and degassed DCE (5 mL), a waterless condenser was attached, and the resulting suspension heated at 70 °C under argon for 72 h. The reaction mixture was then cooled to room temperature, DMSO (0.02 mL, 0.281 mmol) added and the suspension gently stirred for a further 24 h. The mixture was filtered through a glass-fritted filter funnel and the resin washed with DCM and MeOH. The peptide was then cleaved from resin and the crude peptide purified by HPLC as described above. No cyclic products were found.
Method 2 -RCM of full-length peptides on resin pre-swollen with lithium chloride: This method was performed according to a previously reported literature procedure. 4 The resin-bound peptide (0.100 mmol) was added to a manual SPPS vessel and bubbled in dry DCM (10 mL) for 30 min with argon. The resin was subsequently washed with degassed DCE (3 x 5 mL), followed by bubbling in a 0.8 M solution of lithium chloride (3 mL) for 2 min. The resin was then filtered and washed with DMF (2 x 5 mL). Bubbling with the lithium chloride solution was repeated twice more before a final wash with DCE (3 mL).
The pre-swollen peptide resin was then added to a solution of Hoveyda-Grubbs Second Generation Catalyst (11.3 mg, 0.0180 mmol) in anhydrous and degassed DCE (3 mL), a waterless condenser was attached, and the resulting suspension refluxed under argon for 70 h. The reaction mixture was cooled to ambient temperature and a second batch of catalyst (39.5 mg, 0.0630 mmol) added. The resulting mixture was then refluxed for a further 24 h. The reaction mixture was then cooled to ambient temperature, filtered and the resin washed with DCM (3 x 5 mL) and DMF (3 x 5 mL). The resin was then suspended
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in DMF (2 mL) and DMSO (1.92 mL, 27.0 mmol) and bubbled with argon for 12 h. The resin was then washed with DMF (3 x 10 mL), DCM (3 x 5 mL) and MeOH (3 x 5 mL). The peptide was then cleaved from resin and the crude peptide purified by HPLC as described above. No cyclic products were found.
Method 3 -RCM of TriA 1 (5-D-Agl, 9-Agl)-2CT nonapeptide on resin: Truncated TriA 1 (5-D-Agl, 9-Agl)-2CT nonapeptide (10) was synthesized using Fmoc-SPPS. RCM of this peptide was then attempted using method 1. No cyclic products were found.
Method 4 -RCM of TriA 1 (5-D-Agl, 9-Agl)-2CT nonapeptide on resin pre-swollen with lithium chloride: RCM of Truncated TriA 1 (5-D-Agl, 9-Agl)-2CT nonapeptide (10) was attempted using method 2. No cyclic products were found.
V. Synthesis of Oct-cTriA 1 (SS) (5)
Oct-TriA 1 (5-D-Cys, 9-Cys) (4) was synthesized by Fmoc-SPPS as described above. The crude peptide from a 0.1 mmol synthesis was re-dissolved in 1:1 water/ACN (16 mL) to make a 6.25 mM stock solution. An aliquot of this stock solution (2.0 mL, 0.0125 mmol) was added to a solution of TFA (1.7 mL, 22.2 mmol) in distilled water (32 mL). The pH was adjusted to pH 6 with solid ammonium bicarbonate, followed by the addition of DMSO (6.8 mL, 7.48 mol). The reaction mixture was stirred for 5 h at ambient temperature and diluted with 1:1 0.1 % aqueous TFA/ACN. The resulting solution was concentrated in vacuo, re-dissolved in 1:1 0.1 % aqueous TFA/ACN (18 mL) and purified by RP-HPLC.
VI. General procedure for peptide cross-linking
An aliquot of thiol 4 stock solution (6.25 mM, 2.0 mL, 0.0125 mmol) was added to a 20 mM solution of ammonium bicarbonate in 1:1 water/ACN (12.2 mL). The pH was adjusted to pH 8 using a 1 M solution of ammonium bicarbonate. A solution of the appropriate dibromo linker (1.46 equiv, 0.0183 mmol) in ACN (1 mL) was then added and the resulting reaction mixture stirred for 2 hours at ambient temperature. TFA (0.1 mL) was then added and the resulting solution concentrated in vacuo to remove ACN. The solution was then frozen, lyophilised and redissolved in minimal 1:1 0.1% aqueous TFA/ACN for purification by RP-HPLC.
VII. Unsuccessful attempts to cross-link peptides using saturated dibromo-linkers
Method 1 -Cross-linking reactions performed at ambient temperature: Reactions were first performed according to the general procedure for peptide cross-linking, with the reaction time adjusted to 24 h. In all instances only unreacted starting material was observed. minutes (20 W) with a 2 min ramp. In these experiments no cyclic products were recovered by HPLC, however peptides in which one of the cysteine residues had been converted to dehydroalanine were found as described above.
VIII. Antimicrobial testing
All minimum inhibitory concentrations (MICs) were determined according to Clinical and Standards Laboratory Institute (CLSI) guidelines. 5 Briefly, peptides were dissolved in Muller-Hinton Broth (MHB) and serial dilutions made across a 96 well plate. Each well was inoculated with a suspension of the required bacterial strain to reach a final inoculum of 5 x 10 5 colony forming units per mL. The MIC was taken as the lowest concentration with no visible growth after 18 hours.
IX. Peptide degradation studies with TriF pep
TriF pep was expressed and purified as previously described. 3 
XI. HPLC and HRMS analysis of peptides
